EXTRAADRENAL EFFECTS OF METYRAPONE INCLUDE INHIBITION OF THE 11-OXOREDUCTASE ACTIVITY OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE - A MODEL FOR11-HSD-I DEFICIENCY
Pw. Raven et al., EXTRAADRENAL EFFECTS OF METYRAPONE INCLUDE INHIBITION OF THE 11-OXOREDUCTASE ACTIVITY OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE - A MODEL FOR11-HSD-I DEFICIENCY, Clinical endocrinology, 43(5), 1995, pp. 637-644
BACKGROUND AND OBJECTIVE Previous studies suggesting effects of metyra
pone on extra-adrenal corticosteroid metabolism have involved signific
ant alterations in plasma cortisol. We have therefore studied effects
of metyrapone on urinary excretion of steroids in a group of patients
treated concurrently with hydrocortisone so that changes in plasma cor
tisol were minimized. DESIGN Replacement doses of hydrocortisone (30 m
g/day) were given concurrently with metyrapone (2-4 g/day) for 2 weeks
. Blood samples were taken and 24-hour urinary steroid collections wer
e made at baseline and after 1 and 2 weeks of treatment. PATIENTS Subj
ects were 6 female patients with major depression from a trial of mety
rapone as an antidepressant. MEASUREMENTS Urinary steroid profiles wer
e measured by gas chromatography; plasma cortisol and urinary free cor
tisol were measured by fluorescence immunoassay. RESULTS Plasma cortis
ol levels were not significantly decreased by treatment, while excreti
on of 11-deoxycortisol metabolites increased eightfold after 2 weeks i
ndicating that concurrent hydrocortisone administration had not suppre
ssed the adrenal. Ratios reflecting 11 beta-hydroxy/11-oxo metabolites
of cortisol were significantly decreased, consistent with inhibition
of the 11-oxoreductase activity of 11 beta-hydroxysteroid dehydrogenas
e (11-HSD). Other changes included significant decreases in the rates
of 5 alpha vs 5 beta and of 20 alpha vs 20 beta reduction of corticost
eroids. CONCLUSIONS Metyrapone has multiple effects on extra-adrenal c
orticosteroid metabolism and is the only agent we know of which select
ively inhibits 11-oxoreductase. Metyrapone thus provides a model for 1
1-HSD I deficiency and a tool for in-vitro studies of cortisol-cortiso
ne interconversion. The results also suggest mechanisms whereby cortic
osteroid effects can be regulated separately from corticosteroid synth
esis.